摘要
细小脲原体为一种支原体,属于正常菌群,定植在人体下生殖道,是腹膜透析相关腹膜炎少见病原体。细小脲原体不能通过革兰染色观察到或经由常规腹膜透析液培养检出,对目前腹膜炎常用一线及二线抗生素具有耐药性,抑制蛋白质合成和拓扑异构酶的药物是主要的治疗选择。宏基因组二代测序有助于及时明确病原体,调整治疗,改善患者预后。
Ureaplasma parvum is a type of mycoplasma and part of the human microbiota,and can be isolated from both female and male genital tracts.It is a rare pathogen in peritoneal dialysis-associated peritonitis.Ureaplasma parvum cannot be detected by Gram staining or conventional peritoneal dialysis effluent cultures.It is resistant to the first-and second-line antibiotics commonly used for peritonitis.Drugs that inhibit protein synthesis and topoisomerase are the main treatment options.Metagenomic next-generation sequencing(mNGS)can help promptly identify the pathogen,adjust treatment,and improve patient outcomes.
作者
周紫娟
杨薇
王海云
高莹莹
陈丽萌
王颖
ZHOU Zijuan;YANG Wei;WANG Haiyun;GAO Yingying;CHEN Limeng;WANG Ying(Department of Nephrology,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100730,China)
出处
《肾脏病与透析肾移植杂志》
CAS
CSCD
2024年第5期485-489,共5页
Chinese Journal of Nephrology,Dialysis & Transplantation
基金
北京协和医院中央高水平医院临床科研专项(2022-PUMCH-B-020)。
关键词
腹膜透析
腹膜炎
细小脲原体
宏基因二代测序
peritoneal dialysis
peritonitis
ureaplasma parvum
metagenomics next-generation sequencing